<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00490022</url>
  </required_header>
  <id_info>
    <org_study_id>31866-A</org_study_id>
    <secondary_id>1K23AG027238-01A1</secondary_id>
    <nct_id>NCT00490022</nct_id>
  </id_info>
  <brief_title>Effect of Dihydrotestosterone (DHT) on Prostate Tissue [Short Title: DHT-3]</brief_title>
  <acronym>DHT-3</acronym>
  <official_title>The Effect of Dihydrotestosterone (DHT) on Prostate Tissue Androgen Concentrations and Inflammation in Normal Men</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Aging (NIA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>ASCEND Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Washington</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to understand the effects of a male hormone normally
      made in the body called Dihydrotestosterone (DHT) on the prostate gland that is located under
      the bladder. The knowledge gained from this study may be used to help in the future to
      develop a safe male hormonal contraceptive to prevent pregnancy, in the safe treatment of low
      male hormone levels in men, and in the treatment and prevention of diseases of the prostate.

      The investigators will be giving DHT in a gel form, to be applied to the skin, or a placebo
      gel (with no active drug in it). The investigators want to see the effects of DHT on levels
      of hormones in the blood and in the prostate gland itself. In addition, the investigators
      will be studying the effects of DHT on the cells and genes expressed within the prostate.

      The effect of DHT on the prostate is not known. Some studies suggest blocking production of
      DHT in the prostate helps growth of the gland with aging (a condition known as benign
      prostatic hyperplasia, or BPH for short) and may prevent prostate cancer. On the other hand,
      DHT administration may shrink the prostate, suggesting it may be beneficial for some men.
      Therefore, further studies looking at the effect of DHT on the prostate are needed.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study, we will examine the in vivo effects of DHT supplementation on the prostate and
      serum inflammatory markers at the molecular level. We hypothesize that increases in serum DHT
      will not increase intraprostatic DHT or prostate epithelial proliferation, and will be
      associated with decreases in markers of systemic inflammation. Normal, healthy, male study
      volunteers will be treated with either placebo gel (Group 1) or DHT gel (Group 2) for one
      month. Serum hormonal and inflammatory measurements will be assessed before, during, and
      after treatment, and the relationship between hormones and inflammatory markers associated
      with cardiovascular risk will be determined. Prostate biopsies will be taken after one month
      of treatment. Prostate tissue will be analyzed for changes in intraprostatic hormone levels
      as well as gene expression following treatment.

      SPECIFIC AIMS:

        1. To determine the effect of increases in serum DHT, without concomitant increases in
           serum T or estrogen, on intraprostatic androgen levels.

        2. To determine the effect of increases in serum DHT, without concomitant increases in
           serum T or estrogen, on prostate epithelial gene expression.

        3. To determine the effect of increases in serum DHT, without concomitant increases in
           serum T or estrogen, on serum lipids and inflammatory markers including C-Reactive
           Protein [CRP], Tumor necrosis factor-alpha [TNFα], Interleukin-6 [IL-6], adiponectin,
           plasminogen activator inhibitor [PAI-I], and leptin.

      We will test the hypothesis in normal men (rather than hypogonadal men) as a &quot;proof of
      principle&quot; investigation. A normal hypothalamic-pituitary-testicular axis and regulation,
      circulating T and DHT levels and intraprostatic androgen concentrations in healthy, normal
      men will permit optimal testing of the hypothesis. Exogenous DHT administration in normal men
      is expected to suppress endogenous gonadotropin and testosterone secretion, compared to more
      variable effects in hypogonadal men that depend on the degree of hypogonadism in these men
      and whether they have primary (testicular) or secondary (hypothalamic-pituitary)
      hypogonadism. Furthermore, intraprostatic T and DHT concentrations and 5 alpha-reductase
      activity (that is androgen-dependent) is expected to be more variable in hypogonadal men,
      depending on the degree of androgen deficiency and circulating T and DHT levels. If results
      in normal men support the hypothesis, subsequent studies could be performed in hypogonadal
      men. Because of the larger variability in circulating and probably intraprostatic androgen
      concentrations in hypogonadal men, these studies will require much larger numbers of
      subjects.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2007</start_date>
  <completion_date type="Actual">January 2009</completion_date>
  <primary_completion_date type="Actual">January 2009</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Prostate Tissue DHT and Testosterone Levels After 28 Days of Treatment With Dihydrotestosterone [DHT] Gel Versus Placebo Gel.</measure>
    <time_frame>28-days</time_frame>
    <description>After 4 weeks of either daily dihydrotestosterone transdermal gel or placebo gel, subjects underwent a prostate biopsy. Intraprostatic hormone concentrations, specifically DHT and Testosterone, were measured. Unit of measure is ng/g.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Prostate Epithelial Cell Proliferation</measure>
    <time_frame>28-days</time_frame>
    <description>Prostate epithelial cell proliferation in the prostate biopsy tissue was measured using Ki-67 immunohistochemical staining of prostate epithelium as a marker of cell proliferation (values are number of Ki-67 positive stained cells per 100 prostate epithelial cells). The placebo and treatment groups were compared.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>DHT gel (70 mg/day) for one month</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo gel for one month</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dihydrotestosterone (DHT) gel (0.7%)</intervention_name>
    <description>DHT gel, 70 mg/day for one month</description>
    <arm_group_label>1</arm_group_label>
    <other_name>17β-Hydroxy-5α-androstane-3-one</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo gel</intervention_name>
    <description>Placebo gel for one month</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males 35-55 years old

          -  Normal serum total testosterone (300 ng/dl-1000 ng/dl)

          -  Normal Luteinizing Hormone [LH] and Follicle Stimulating Hormone [FSH] levels

          -  Informed consent

          -  Taking no regular medications

          -  Normal baseline prostate ultrasound, hematology, and liver function tests

        Exclusion Criteria:

          -  History of prostate cancer

          -  Prostate Specific Antigen [PSA] &gt; 2.0

          -  American Urological Association [AUA] prostate symptom score &gt; 10

          -  History of testosterone or anabolic steroid use in the past

          -  Chronic medical illness or prostate disease

          -  History of a bleeding disorder or need for anticoagulation

          -  A first-degree relative (i.e. father, brother) with a history of prostate cancer

          -  Abnormal digital rectal examination

          -  Skin condition that might interfere with or be exacerbated by DHT gel use

          -  History of untreated sleep apnea and/or psychiatric problems

          -  Participation in another study in the past 2 months

          -  Participating in a regular physical relationship with a pregnant woman
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephanie T Page, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Washington</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://depts.washington.edu/popctr/</url>
    <description>http://depts.washington.edu/popctr/is Dedicated to basic and clinical research focused primarily on the male reproductive system.</description>
  </link>
  <reference>
    <citation>Huggins C, Hodges CV. Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941. J Urol. 2002 Jul;168(1):9-12.</citation>
    <PMID>12050481</PMID>
  </reference>
  <reference>
    <citation>Bhasin S, Singh AB, Mac RP, Carter B, Lee MI, Cunningham GR. Managing the risks of prostate disease during testosterone replacement therapy in older men: recommendations for a standardized monitoring plan. J Androl. 2003 May-Jun;24(3):299-311. Review.</citation>
    <PMID>12721204</PMID>
  </reference>
  <reference>
    <citation>Morgentaler A, Bruning CO 3rd, DeWolf WC. Occult prostate cancer in men with low serum testosterone levels. JAMA. 1996 Dec 18;276(23):1904-6.</citation>
    <PMID>8968017</PMID>
  </reference>
  <reference>
    <citation>Schatzl G, Madersbacher S, Thurridl T, Waldmüller J, Kramer G, Haitel A, Marberger M. High-grade prostate cancer is associated with low serum testosterone levels. Prostate. 2001 Apr;47(1):52-8.</citation>
    <PMID>11304729</PMID>
  </reference>
  <reference>
    <citation>Wu FC, von Eckardstein A. Androgens and coronary artery disease. Endocr Rev. 2003 Apr;24(2):183-217. Review.</citation>
    <PMID>12700179</PMID>
  </reference>
  <reference>
    <citation>Bagatell CJ, Heiman JR, Matsumoto AM, Rivier JE, Bremner WJ. Metabolic and behavioral effects of high-dose, exogenous testosterone in healthy men. J Clin Endocrinol Metab. 1994 Aug;79(2):561-7.</citation>
    <PMID>8045977</PMID>
  </reference>
  <reference>
    <citation>Bartsch W, Klein H, Schiemann U, Bauer HW, Voigt KD. Enzymes of androgen formation and degradation in the human prostate. Ann N Y Acad Sci. 1990;595:53-66. Review.</citation>
    <PMID>1695829</PMID>
  </reference>
  <reference>
    <citation>Bartsch W, Krieg M, Becker H, Mohrmann J, Voigt KD. Endogenous androgen levels in epithelium and stroma of human benign prostatic hyperplasia and normal prostate. Acta Endocrinol (Copenh). 1982 Aug;100(4):634-40.</citation>
    <PMID>6181638</PMID>
  </reference>
  <reference>
    <citation>Page ST, Lin DW, Mostaghel EA, Hess DL, True LD, Amory JK, Nelson PS, Matsumoto AM, Bremner WJ. Persistent intraprostatic androgen concentrations after medical castration in healthy men. J Clin Endocrinol Metab. 2006 Oct;91(10):3850-6. Epub 2006 Aug 1.</citation>
    <PMID>16882745</PMID>
  </reference>
  <reference>
    <citation>Wilson JD. The role of 5alpha-reduction in steroid hormone physiology. Reprod Fertil Dev. 2001;13(7-8):673-8. Review.</citation>
    <PMID>11999320</PMID>
  </reference>
  <reference>
    <citation>Andriole GL, Humphrey P, Ray P, Gleave ME, Trachtenberg J, Thomas LN, Lazier CB, Rittmaster RS. Effect of the dual 5alpha-reductase inhibitor dutasteride on markers of tumor regression in prostate cancer. J Urol. 2004 Sep;172(3):915-9.</citation>
    <PMID>15310997</PMID>
  </reference>
  <reference>
    <citation>Norman RW, Coakes KE, Wright AS, Rittmaster RS. Androgen metabolism in men receiving finasteride before prostatectomy. J Urol. 1993 Nov;150(5 Pt 2):1736-9.</citation>
    <PMID>7692110</PMID>
  </reference>
  <reference>
    <citation>Kunelius P, Lukkarinen O, Hannuksela ML, Itkonen O, Tapanainen JS. The effects of transdermal dihydrotestosterone in the aging male: a prospective, randomized, double blind study. J Clin Endocrinol Metab. 2002 Apr;87(4):1467-72.</citation>
    <PMID>11932266</PMID>
  </reference>
  <reference>
    <citation>Ly LP, Jimenez M, Zhuang TN, Celermajer DS, Conway AJ, Handelsman DJ. A double-blind, placebo-controlled, randomized clinical trial of transdermal dihydrotestosterone gel on muscular strength, mobility, and quality of life in older men with partial androgen deficiency. J Clin Endocrinol Metab. 2001 Sep;86(9):4078-88.</citation>
    <PMID>11549629</PMID>
  </reference>
  <reference>
    <citation>Nelson PS, Clegg N, Arnold H, Ferguson C, Bonham M, White J, Hood L, Lin B. The program of androgen-responsive genes in neoplastic prostate epithelium. Proc Natl Acad Sci U S A. 2002 Sep 3;99(18):11890-5. Epub 2002 Aug 16.</citation>
    <PMID>12185249</PMID>
  </reference>
  <verification_date>June 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 20, 2007</study_first_submitted>
  <study_first_submitted_qc>June 21, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 22, 2007</study_first_posted>
  <results_first_submitted>January 10, 2011</results_first_submitted>
  <results_first_submitted_qc>May 10, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 9, 2011</results_first_posted>
  <last_update_submitted>June 20, 2011</last_update_submitted>
  <last_update_submitted_qc>June 20, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 27, 2011</last_update_posted>
  <responsible_party>
    <name_title>Stephanie T Page, MD, PhD</name_title>
    <organization>University of Washington</organization>
  </responsible_party>
  <keyword>Dihydrotestosterone</keyword>
  <keyword>Androgen</keyword>
  <keyword>Prostate</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Androgens</mesh_term>
    <mesh_term>Dihydrotestosterone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Up to 55 normal, healthy men between the ages of 35-55 will be recruited for this study. All subject activities will occur at the University of Washington in Seattle Washington.</recruitment_details>
      <pre_assignment_details>Subjects must meet all study protocol inclusion criteria such as informed consent, normal lab values, normal physical examination and normal prostate ultrasound, and not have exclusion criteria such as a first degree relative with or personal history of prostate cancer, PSA &gt;2.0 or a history of a bleeding disorder or need for anticoagulation.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo DHT Gel</title>
          <description>Placebo gel for one month</description>
        </group>
        <group group_id="P2">
          <title>DHT Gel</title>
          <description>DHT gel (70 mg/day) for one month</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject failed to disclose concommitant</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo DHT Gel</title>
          <description>Placebo gel for one month</description>
        </group>
        <group group_id="B2">
          <title>DHT Gel</title>
          <description>DHT gel (70 mg/day) for one month</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="16"/>
            <count group_id="B2" value="15"/>
            <count group_id="B3" value="31"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44.4" spread="6.7"/>
                    <measurement group_id="B2" value="42.7" spread="1.6"/>
                    <measurement group_id="B3" value="43.6" spread="4.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Prostate Tissue DHT and Testosterone Levels After 28 Days of Treatment With Dihydrotestosterone [DHT] Gel Versus Placebo Gel.</title>
        <description>After 4 weeks of either daily dihydrotestosterone transdermal gel or placebo gel, subjects underwent a prostate biopsy. Intraprostatic hormone concentrations, specifically DHT and Testosterone, were measured. Unit of measure is ng/g.</description>
        <time_frame>28-days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo DHT Gel</title>
            <description>Placebo gel for one month</description>
          </group>
          <group group_id="O2">
            <title>DHT Gel</title>
            <description>DHT gel (70 mg/day) for one month</description>
          </group>
        </group_list>
        <measure>
          <title>Prostate Tissue DHT and Testosterone Levels After 28 Days of Treatment With Dihydrotestosterone [DHT] Gel Versus Placebo Gel.</title>
          <description>After 4 weeks of either daily dihydrotestosterone transdermal gel or placebo gel, subjects underwent a prostate biopsy. Intraprostatic hormone concentrations, specifically DHT and Testosterone, were measured. Unit of measure is ng/g.</description>
          <units>ng/g</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>DHT concentrations</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8" spread="0.2"/>
                    <measurement group_id="O2" value="3.1" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Testosterone Concentrations</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" spread="0.2"/>
                    <measurement group_id="O2" value="0.4" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Prostate Epithelial Cell Proliferation</title>
        <description>Prostate epithelial cell proliferation in the prostate biopsy tissue was measured using Ki-67 immunohistochemical staining of prostate epithelium as a marker of cell proliferation (values are number of Ki-67 positive stained cells per 100 prostate epithelial cells). The placebo and treatment groups were compared.</description>
        <time_frame>28-days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo DHT Gel</title>
            <description>Placebo gel for one month</description>
          </group>
          <group group_id="O2">
            <title>DHT Gel</title>
            <description>DHT gel (70 mg/day) for one month</description>
          </group>
        </group_list>
        <measure>
          <title>Prostate Epithelial Cell Proliferation</title>
          <description>Prostate epithelial cell proliferation in the prostate biopsy tissue was measured using Ki-67 immunohistochemical staining of prostate epithelium as a marker of cell proliferation (values are number of Ki-67 positive stained cells per 100 prostate epithelial cells). The placebo and treatment groups were compared.</description>
          <units>#pos.Ki-67cells per100 prst. epth cells</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" spread="0.5"/>
                    <measurement group_id="O2" value="0.7" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Placebo DHT Gel</title>
          <description>Placebo gel for one month</description>
        </group>
        <group group_id="E2">
          <title>DHT Gel</title>
          <description>DHT gel (70 mg/day) for one month</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Rectal Bleed</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary Frequency</sub_title>
                <description>Subject experienced urinary frequency. It resolved after discontinuation of DHT gel.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Stephanie Page, PhD, MD</name_or_title>
      <organization>University of Washington</organization>
      <phone>206.616.0483</phone>
      <email>page@u.washington.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

